AVAR

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: AVAR
Generic name: SULFACETAMIDE SODIUM, SULFUR
Manufacturer: Mission Pharmacal Company
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: 88e4070f-0538-463d-b9a7-98a4e8979cd1
SPL ID: 47e77005-1215-779a-e063-6394a90a5b28
Version: 7
Effective date: 2026-01-08
Source export date: 2026-11-06
Source partition: 7
Source file: https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-11-06/824fe785252d7061429a95ddb6de517ee399ef628d34e8fdcc3591ded286ae33/drug-label-0007-of-0014.json.zip
Source manifest SHA-256: 4a7570ba105b5a039a8e1c94a85e7f085b9047a8882a35a96bf1e4516c5ffc97
Import run: 20261108T063105Z
Imported at: 2026-11-08 07:25:30

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 12 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
brand name		AVAR	openfda.brand_name
generic name		SULFACETAMIDE SODIUM, SULFUR	openfda.generic_name
manufacturer name		Mission Pharmacal Company	openfda.manufacturer_name
ndc	package	0178-0480-08	openfda.package_ndc
ndc	product	0178-0480	openfda.product_ndc
ndc11	package	00178048008	derived:openfda.package_ndc
rxcui		1005767	openfda.rxcui
rxcui		999613	openfda.rxcui
spl id		47e77005-1215-779a-e063-6394a90a5b28	id
spl set id		88e4070f-0538-463d-b9a7-98a4e8979cd1	set_id
unii		4NRT660KJQ	openfda.unii
unii		70FD1KFU70	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.